Allurion Technologies (Allurion Technologies) ROCE % : 112,488.89% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Allurion Technologies's annualized ROCE % for the quarter that ended in Mar. 2024 was 112,488.89%.

Allurion Technologies ROCE % Historical Data

The historical data trend for Allurion Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies ROCE % Chart

Allurion Technologies Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-112.64

Allurion Technologies Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial					-	-	-	-317.43	112,488.89

Allurion Technologies ROCE % Calculation

Allurion Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-69.777	/	( ( (51.37 - 75.867)	+	(71.712 - 65.425) )	/ 2 )
	=	-69.777	/	( (-24.497	+	6.287)	/ 2 )
	=	-69.777	/	-9.105
	=	766.36 %

Allurion Technologies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	30.372	/	( ( (71.712 - 65.425)	+	(59.988 - 66.221) )	/ 2 )
	=	30.372	/	( ( 6.287	+	-6.233 )	/ 2 )
	=	30.372	/	0.027000000000001
	=	112,488.89 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Allurion Technologies (NYSE:ALUR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Allurion Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Allurion Technologies (Allurion Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Huron Drive, Natick, MA, USA, 01760

Website

Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Executives

Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta	director, 10 percent owner	307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth	officer: Chief Financial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin	director	C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson	director	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon	officer: Chief Commercial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur	director, officer: Chief Executive Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani	officer: Chief Medical Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760